Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 397

1.

Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.

Armer JM, Ballman KV, McCall L, Ostby PL, Zagar E, Kuerer HM, Hunt KK, Boughey JC.

JAMA Surg. 2019 Jul 17. doi: 10.1001/jamasurg.2019.1742. [Epub ahead of print]

PMID:
31314062
2.

Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach.

Stecklein SR, Rosso KJ, Nuanjing J, Tadros AB, Weiss A, DeSnyder SM, Kuerer HM, Teshome M, Buchholz TA, Stauder MC, Ueno NT, Lucci A, Woodward WA.

Pract Radiat Oncol. 2019 May 24. pii: S1879-8500(19)30142-0. doi: 10.1016/j.prro.2019.05.011. [Epub ahead of print]

PMID:
31132433
3.

Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF.

Breast Cancer Res Treat. 2019 Jul;176(2):435-444. doi: 10.1007/s10549-019-05243-7. Epub 2019 Apr 25.

PMID:
31025270
4.

Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery.

Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM.

Ann Surg Oncol. 2019 Jun;26(6):1720-1728. doi: 10.1245/s10434-019-07226-w. Epub 2019 Mar 14.

PMID:
30877499
5.

Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.

Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):574-581. doi: 10.1016/j.ijrobp.2019.02.049. Epub 2019 Mar 6.

PMID:
30851348
6.

Surgeon perception versus reality: Opioid use after breast cancer surgery.

Park KU, Kyrish K, Terrell J, Yi M, Caudle AS, Hunt KK, Kuerer HM, Bedrosian I, Thompson A, DeSnyder SM; other members of Department of Breast Surgical Oncology Study Group.

J Surg Oncol. 2019 Jun;119(7):909-915. doi: 10.1002/jso.25395. Epub 2019 Feb 8.

PMID:
30737785
7.

OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients.

Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF.

Ann Surg Oncol. 2019 Mar;26(3):815-820. doi: 10.1245/s10434-018-7059-4. Epub 2018 Dec 17.

PMID:
30556120
8.

Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.

Caudle AS, Kuerer HM, Krishnamurthy S, Shin K, Hobbs BP, Ma J, Mittendorf EA, Washington AC, DeSnyder SM, Black DM, Hunt KK, Yang WT.

Cancer. 2019 Feb 1;125(3):365-373. doi: 10.1002/cncr.31825. Epub 2018 Oct 25.

PMID:
30359480
9.

More evidence for further minimisation of breast-cancer surgery.

Kuerer HM.

Lancet Oncol. 2018 Oct;19(10):1272-1273. doi: 10.1016/S1470-2045(18)30416-9. Epub 2018 Sep 5. No abstract available.

PMID:
30196032
10.

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.

Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC.

JAMA Surg. 2018 Sep 5. doi: 10.1001/jamasurg.2018.2696. [Epub ahead of print]

PMID:
30193375
11.

Increasing Breast Cancer Systemic Therapy Use Before Surgery in the United States: Scaling Down and the Promise of Selective Elimination of Surgery.

Kuerer HM.

Ann Surg Oncol. 2018 Oct;25(11):3115-3118. doi: 10.1245/s10434-018-6643-y. Epub 2018 Jul 26. No abstract available.

PMID:
30051370
12.

American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation.

DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A.

Ann Surg Oncol. 2018 Oct;25(10):2965-2974. doi: 10.1245/s10434-018-6580-9. Epub 2018 Jul 9.

PMID:
29987598
13.

Patient-Reported Outcomes for Breast Cancer.

Tevis SE, James TA, Kuerer HM, Pusic AL, Yao KA, Merlino J, Dietz J.

Ann Surg Oncol. 2018 Oct;25(10):2839-2845. doi: 10.1245/s10434-018-6616-1. Epub 2018 Jul 3. Review.

PMID:
29971671
14.

The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations.

Ollila DW, Hwang ES, Brenin DR, Kuerer HM, Yao K, Feldman S.

Ann Surg Oncol. 2018 Oct;25(10):2807-2812. doi: 10.1245/s10434-018-6618-z. Epub 2018 Jul 2. Review.

PMID:
29968033
15.

Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins.

Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS.

Ann Surg Oncol. 2018 Oct;25(10):2932-2938. doi: 10.1245/s10434-018-6607-2. Epub 2018 Jun 26.

PMID:
29947001
16.

Breast cancer metastasis through the lympho-vascular system.

Nathanson SD, Krag D, Kuerer HM, Newman LA, Brown M, Kerjaschki D, Pereira ER, Padera TP.

Clin Exp Metastasis. 2018 Aug;35(5-6):443-454. doi: 10.1007/s10585-018-9902-1. Epub 2018 May 23. Review.

PMID:
29796854
17.

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.

Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK.

Cancer Med. 2018 Jun;7(6):2718-2726. doi: 10.1002/cam4.1519. Epub 2018 May 7.

18.
19.

Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.

Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT.

Ann Surg Oncol. 2018 Jul;25(7):1953-1960. doi: 10.1245/s10434-018-6481-y. Epub 2018 Apr 17.

PMID:
29667115
20.

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.

Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.

Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.

21.

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM.

Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.

PMID:
29465744
22.

Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trials.

Kuerer HM.

Eur J Surg Oncol. 2018 Apr;44(4):386-387. doi: 10.1016/j.ejso.2017.12.005. Epub 2018 Jan 10. No abstract available.

PMID:
29398321
23.

Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer.

van la Parra RFD, Liao K, Smith BD, Yang WT, Leung JWT, Giordano SH, Kuerer HM.

JAMA Surg. 2018 Jun 1;153(6):559-568. doi: 10.1001/jamasurg.2017.5572.

24.

Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.

Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS.

Clin Breast Cancer. 2018 Aug;18(4):276-281. doi: 10.1016/j.clbc.2017.10.007. Epub 2017 Oct 13.

PMID:
29100726
25.

Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V.

Ann Surg. 2018 Dec;268(6):e61-e62. doi: 10.1097/SLA.0000000000002573. No abstract available.

PMID:
29064904
26.

DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes.

Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK.

J Cancer. 2017 Aug 22;8(14):2653-2662. doi: 10.7150/jca.20871. eCollection 2017. Review.

27.

Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery.

Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A.

Ann Surg Oncol. 2017 Oct;24(10):2981-2988. doi: 10.1245/s10434-017-5952-x. Epub 2017 Aug 1.

PMID:
28766220
28.

A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction.

Ayoub Z, Strom EA, Ovalle V, Perkins GH, Woodward WA, Tereffe W, Smith BD, Shaitelman SF, Stauder MC, Hoffman KE, DeSnyder SM, Garvey PB, Clemens MW, Barcenas CH, Kuerer HM, Kronowitz S.

Ann Surg Oncol. 2017 Oct;24(10):2965-2971. doi: 10.1245/s10434-017-5956-6. Epub 2017 Aug 1.

PMID:
28766219
29.

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA.

Ann Surg Oncol. 2017 Oct;24(10):2925-2934. doi: 10.1245/s10434-017-5958-4. Epub 2017 Aug 1.

30.

Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.

Kuerer HM, Vrancken Peeters MTFD, Rea DW, Basik M, De Los Santos J, Heil J.

Ann Surg Oncol. 2017 Oct;24(10):2855-2862. doi: 10.1245/s10434-017-5926-z. Epub 2017 Aug 1.

PMID:
28766204
31.

Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.

DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A.

Clin Breast Cancer. 2018 Feb;18(1):e73-e77. doi: 10.1016/j.clbc.2017.06.014. Epub 2017 Jul 10.

PMID:
28755879
32.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM.

Ann Surg. 2019 Jan;269(1):150-157. doi: 10.1097/SLA.0000000000002439.

PMID:
28742682
33.

NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence.

Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1028-1035. doi: 10.1016/j.ijrobp.2017.03.016. Epub 2017 Mar 18.

34.

Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer.

Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, DeSnyder SM, Barcenas CH, Lucci A.

Am J Surg. 2017 Oct;214(4):666-671. doi: 10.1016/j.amjsurg.2017.06.005. Epub 2017 Jun 23.

35.

Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.

Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF.

Breast J. 2018 Jan;24(1):28-34. doi: 10.1111/tbj.12829. Epub 2017 Jun 13.

36.

Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery.

Kuerer HM, Cordeiro PG, Mutter RW.

Am Soc Clin Oncol Educ Book. 2017;37:93-105. doi: 10.14694/EDBK_175342. Review.

PMID:
28561684
37.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

38.

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.

Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM.

JAMA Surg. 2017 Jul 1;152(7):665-670. doi: 10.1001/jamasurg.2017.0562. Erratum in: JAMA Surg. 2017 Jul 1;152(7):708.

39.

Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Candelaria RP, Bassett RL, Symmans WF, Ramineni M, Moulder SL, Kuerer HM, Thompson AM, Yang WT.

Oncologist. 2017 Apr;22(4):394-401. doi: 10.1634/theoncologist.2016-0307. Epub 2017 Mar 17.

40.

Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.

Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y.

Cancer. 2017 Jul 15;123(14):2618-2625. doi: 10.1002/cncr.30660. Epub 2017 Mar 13.

41.

Breast conserving surgery and locoregional control after neoadjuvant chemotherapy.

Teshome M, Kuerer HM.

Eur J Surg Oncol. 2017 May;43(5):865-874. doi: 10.1016/j.ejso.2017.02.002. Epub 2017 Feb 12. Review.

PMID:
28284519
42.

Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction.

Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ.

Plast Reconstr Surg. 2017 Mar;139(3):586e-596e. doi: 10.1097/PRS.0000000000003050.

PMID:
28234813
43.

DCIS and axillary nodal evaluation: compliance with national guidelines.

Mitchell KB, Lin H, Shen Y, Colfry A, Kuerer H, Shaitelman SF, Babiera GV, Bedrosian I.

BMC Surg. 2017 Feb 7;17(1):12. doi: 10.1186/s12893-017-0210-5.

44.

A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative.

Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, Allison KH, Benn KE, Browne JP, Cooter RD, Delaney GP, Duhoux FP, Ganz PA, Hancock P, Jagsi R, Knaul FM, Knip AM, Koppert LB, Kuerer HM, McLaughin S, Mureau MAM, Partridge AH, Reid DP, Sheeran L, Smith TJ, Stoutjesdijk MJ, Vrancken Peeters MJTFD, Wengström Y, Yip CH, Saunders C.

JAMA Oncol. 2017 May 1;3(5):677-685. doi: 10.1001/jamaoncol.2016.4851.

PMID:
28033439
45.

Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer.

Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT.

Acad Radiol. 2017 Feb;24(2):191-199. doi: 10.1016/j.acra.2016.11.015. Epub 2016 Dec 7.

46.

Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment.

Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT.

AJR Am J Roentgenol. 2017 Feb;208(2):248-255. doi: 10.2214/AJR.16.17130. Epub 2016 Dec 8. Review.

47.

Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R.

Ann Surg Oncol. 2017 Mar;24(3):652-659. doi: 10.1245/s10434-016-5605-5. Epub 2016 Oct 3.

48.

Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer.

Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT.

AJR Am J Roentgenol. 2017 Feb;208(2):290-299. doi: 10.2214/AJR.16.17223. Epub 2016 Nov 3. Review.

PMID:
27809573
49.

Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision.

Shin K, Caudle AS, Kuerer HM, Santiago L, Candelaria RP, Dogan B, Leung J, Krishnamurthy S, Yang W.

AJR Am J Roentgenol. 2016 Dec;207(6):1372-1379. Epub 2016 Oct 11.

PMID:
27726422
50.

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.

Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J; Study investigators and study participants.

Ann Surg Oncol. 2017 Mar;24(3):660-668. doi: 10.1245/s10434-016-5583-7. Epub 2016 Oct 4.

Supplemental Content

Loading ...
Support Center